4.6 Review

Clonal Hematopoiesis of Indeterminate Potential From a Heart Failure Specialist's Point of View

期刊

出版社

WILEY
DOI: 10.1161/JAHA.123.030603

关键词

atherosclerotic cardiovascular disease; clonal hematopoiesis; heart failure; inflammation

向作者/读者索取更多资源

Clonal hematopoiesis of indeterminate potential (CHIP) is a common bone marrow abnormality caused by age-related DNA mutations, which leads to the production of proinflammatory immune cells. These immune cells aggravate atherosclerotic cardiovascular disease and may contribute to heart failure. The mechanisms involved suggest that proinflammatory macrophages and an inflammasome-dependent immune response play a central role. Intracardiac inflammation can decrease cardiac function and induce cardiac fibrosis, even without the presence of atherosclerotic cardiovascular disease. The pathophysiology and consequences of CHIP can vary depending on the implicated genes and subgroups of heart failure patients.
Clonal hematopoiesis of indeterminate potential (CHIP) is a common bone marrow abnormality induced by age-related DNA mutations, which give rise to proinflammatory immune cells. These immune cells exacerbate atherosclerotic cardiovascular disease and may induce or accelerate heart failure. The mechanisms involved are complex but point toward a central role for proinflammatory macrophages and an inflammasome-dependent immune response (IL-1 [interleukin-1] and IL-6 [interleukin-6]) in the atherosclerotic plaque or directly in the myocardium. Intracardiac inflammation may decrease cardiac function and induce cardiac fibrosis, even in the absence of atherosclerotic cardiovascular disease. The pathophysiology and consequences of CHIP may differ among implicated genes as well as subgroups of patients with heart failure, based on cause (ischemic versus nonischemic) and ejection fraction (reduced ejection fraction versus preserved ejection fraction). Evidence is accumulating that CHIP is associated with cardiovascular mortality in ischemic and nonischemic heart failure with reduced ejection fraction and involved in the development of heart failure with preserved ejection fraction. CHIP and corresponding inflammatory pathways provide a highly potent therapeutic target. Randomized controlled trials in patients with well-phenotyped heart failure, where readily available anti-inflammatory therapies are used to intervene with clonal hematopoiesis, may pave the way for a new area of heart failure treatment. The first clinical trials that target CHIP are already registered.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据